Semaglutide: Ozempic, Wegovy & Rybelsus

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of prescription drug that mimics the action of GLP-1, a hormone naturally released by the gut after eating. Semaglutide was developed by Novo Nordisk and has been approved by the FDA in multiple formulations for two conditions: type 2 diabetes and chronic weight management.

Semaglutide acts by binding to GLP-1 receptors throughout the body — particularly in the pancreas, brain, and gastrointestinal tract. This produces several effects: increased insulin secretion (in a glucose-dependent manner), reduced glucagon secretion, slowed gastric emptying, and reduced appetite. The combination of these effects produces better blood sugar control and, as a secondary effect, weight reduction.

Semaglutide is structurally similar to human GLP-1 but is chemically modified to have a much longer half-life — approximately one week. This is what makes once-weekly dosing possible for injectable formulations.

FDA-Approved Products Containing Semaglutide

All three products are manufactured by Novo Nordisk and are prescription-only. They contain the same active ingredient but differ in dose, delivery route, and FDA-approved indication.

Differences Between Ozempic and Wegovy

Despite sharing the same active ingredient, Ozempic and Wegovy are distinct FDA-approved products:

• Indication: Ozempic is approved for type 2 diabetes; Wegovy for chronic weight management.
• Maximum dose: Ozempic's maximum approved dose is 2.0 mg weekly; Wegovy's is 2.4 mg weekly.
• Insurance coverage: Ozempic is more commonly covered by insurance (diabetes indication); Wegovy coverage is less consistent (weight management).
• Clinical trials: Ozempic was studied in SUSTAIN trials for diabetes; Wegovy in STEP trials for weight management. The patient populations and endpoints differed.

For people with type 2 diabetes seeking GLP-1 treatment, Ozempic may be directly on-label. For people seeking weight management without type 2 diabetes, Wegovy is the on-label option. A licensed clinician determines which product is appropriate for your situation.

Rybelsus: The Oral Semaglutide Option

Rybelsus is the only oral GLP-1 receptor agonist currently FDA-approved. It is semaglutide in tablet form, taken once daily on an empty stomach with a small amount of water. It is FDA-approved for type 2 diabetes management — not for weight management.

Because it is taken orally rather than injected, Rybelsus is preferred by some patients who are averse to injections. However, it requires specific administration conditions (taken 30 minutes before eating, with no more than 4 oz of water) to ensure adequate absorption. Its weight loss effects are generally less pronounced than injectable semaglutide at the approved doses.

Compounded Semaglutide: What to Know

Compounded semaglutide refers to preparations made by licensed compounding pharmacies using bulk semaglutide API (active pharmaceutical ingredient). It is distinct from the FDA-approved products described above in important ways:

• Compounded semaglutide is not FDA-approved — it has not undergone the clinical trial and manufacturing review process required of Ozempic, Wegovy, or Rybelsus.
• It is not a generic version of any semaglutide product. FDA-approved generics require a full abbreviated new drug application (ANDA) process.
• The legal status of compounded semaglutide is tied to FDA drug shortage list status — it has been subject to changing regulations.
• The FDA has issued warnings about compounded semaglutide products, including concerns about dosing errors, counterfeit products, and illegal marketing.

For a full discussion, see our compounded GLP-1 medications guide.